英文字典中文字典


英文字典中文字典51ZiDian.com



中文字典辞典   英文字典 a   b   c   d   e   f   g   h   i   j   k   l   m   n   o   p   q   r   s   t   u   v   w   x   y   z       







请输入英文单字，中文词皆可：

sunburnt    

安装中文字典英文字典查询工具!


中文字典英文字典工具:
选择颜色:
输入中英文单字

































































英文字典中文字典相关资料:


  • Adstiladrin: Uses, Dosage, Side Effects Warnings - Drugs. com
    Adstiladrin (nadofaragene firadenovec-vncg) is a gene therapy used to treat high-risk Bacillus CalmetteGuérin (BCG)-unresponsive non-muscle invasive bladder cancer Includes Adstiladrin side effects, interactions and indications
  • Ferring Announces Update to NCCN Guidelines Expanding . . .
    Ferring Pharmaceuticals announces that nadofaragene firadenovec-vncg (ADSTILADRIN ®) has been upgraded to a National Comprehensive Cancer Network® (NCCN®) Ca
  • NCCN upgrades recommendation for nadofaragene firadenovec in . . .
    An update to the 2026 National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology has elevated the recommendation for nadofaragene firadenovec-vncg (Adstiladrin) in select patients with BCG-unresponsive non–muscle invasive bladder cancer (NMIBC), Ferring Pharmaceuticals announced in a news release 1
  • Package Insert - ADSTILADRIN
    ADSTILADRIN® is indicated for the treatment of adult patients with high-risk Bacillus Calmette-Guérin (BCG)-unresponsive non-Muscle Invasive Bladder Cancer (NMIBC) with carcinoma in situ (CIS
  • FDA Approval Summary: Nadofaragene Firadenovec-vncg for . . .
    Abstract On December 16, 2022, the FDA approved the adenoviral vector-based gene therapy nadofaragene firadenovec-vncg (brand name Adstiladrin) for the treatment of adult patients with high-risk Bacillus Calmette-Guérin (BCG)-unresponsive non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ (CIS) The product represents the first approved adenoviral vector-based gene therapy and
  • Nadofaragene firadenovec-vncg (ADSTILADRIN) National Drug . . .
    Nadofaragene firadenovec uses a recombinant adenovirus that encodes for interferon alpha-2b gene Intravesical instillation of interferon alone for bladder cancer produced complete responses that were short lived in previous studies
  • Nadofaragene Firadenovec Is Added to NCCN Guidelines in BCG . . .
    The National Comprehensive Cancer Network (NCCN) has updated its Clinical Practice Guidelines in Oncology for bladder cancer to include nadofaragene firadenovec-vncg (Adstiladrin) as a category 2A
  • Real-World Evidence - ADSTILADRIN® (nadofaragene firadenovec . . .
    Real-World Outcomes of ADSTILADRIN in BCG-Unresponsive NMIBC 1 Methods Patients with Bacillus Calmette-Guérin (BCG)-unresponsive non–muscle-invasive bladder cancer (NMIBC) treated with ADSTILADRIN were retrospectively analyzed at 3 Mayo Clinic sites from November 2023 to December 2024 Outcomes included complete response (CR) rate, duration
  • ADSTILADRIN | FDA
    ADSTILADRIN is indicated for the treatment of adult patients with high-risk Bacillus Calmette-Guérin (BCG)-unresponsive non-Muscle Invasive Bladder Cancer (NMIBC) with carcinoma in situ (CIS
  • Ferring Receives Approval from U. S. FDA for Adstiladrin for . . .
    Ferring’s novel adenovirus vector-based gene therapy Adstiladrin® (nadofaragene firadenovec-vncg) is the first gene therapy approved for bladder cancer Efficacy and safety of Adstiladrin supported by Phase 3 results demonstrating that more than half of patients (51% of CIS ± Ta T1 cohort) achieved a complete response (CR) at three months and of these, 46% continued to remain free of high





中文字典-英文字典  2005-2009